Millennium/Takeda's Phase III IBD Drug Promises Improved Safety
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium Pharmaceuticals has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease, the Takeda subsidiary announced Jan. 2